 |
Vol.57 No.3 contents | Japanese/English |
 | Full Text of PDF (313K) Article in Japanese |
- Original Article -
Effectiveness of S-1 Monotherapy for Non-small-cell Lung Cancer Associated with Interstitial Pneumonia
Takahiro Yoshizawa1, Kazutoshi Isobe1, Kyohei Kaburaki1, Hiroshi Kobayashi1, Go Sano1, Keishi Sugino1, Susumu Sakamoto1, Yujiro Takai1, Naobumi Tochigi2, Sakae Homma11Department of Internal Medicine, Division of Respiratory Medicine, 2Department of Surgical Pathology, Toho University Omori Medical Center, Japan
Objective. To evaluate the effectiveness and safety of S-1 monotherapy for lung cancer associated with interstitial pneumonia (IP). Methods. The medical records of 15 patients with lung cancer-associating IP from April 2005 through March 2015 were retrospectively evaluated to determine the clinical response, adverse effects, and frequency of acute respiratory deterioration after S-1 monotherapy. Results. The median age was 73 (range, 64-80) years, the male/female ratio was 13/2, and 14 patients were smokers. The Eastern Cooperative Oncology Group performance status was 0/1/2/3 in 2/5/5/3 patients, respectively. The epidermal growth factor receptor mutation status was positive, negative, and unknown in 1/9/5 patients, respectively. The histopathological type was adenocarcinoma in 8, squamous cell carcinoma in 5, and other in 2 patients. The clinical stage was I/II/IIIA/IIIB/IV/postoperative recurrence in 2, 0, 2, 3, 6, and 2 patients, respectively. S-1 monotherapy was given as first-/second-/third-/fourth-line or later chemotherapy in 3, 1, 4, and 7 patients, respectively. The IP pattern was usual IP in 11 patients and non-usual IP in 4 patients. The median number of S-1 monotherapy cycles was 2 (range, 1-6); each cycle continued for 4 weeks, followed by a 2-week rest period. The median progression-free survival after S-1 monotherapy was 71 (range, 12-293) days, and the median survival time was 329 (range, 24-1291) days. There were no cases of acute respiratory deterioration after S-1 monotherapy. Conclusion. S-1 monotherapy was safe and effective for patients with lung cancer-associating IP, including those with a poor performance status and those who had previously received multiple lines of chemotherapy.
key words: Primary lung cancer, Interstitial pneumonia associated with lung cancer, Anti-cancer therapy related acute respiratory deterioration, S-1
Received: November 2, 2016
Accepted: March 29, 2017
JJLC 57 (3): 184-189, 2017
